BURLINGTON, Mass., Jan. 22, 2014 /PRNewswire/ -- According to Decision Resources Group (DRG), compared to other regions, the Brazilian, Russian, Indian and Chinese (BRIC) markets for dental biomaterials are extremely underpenetrated. Particularly in Brazil and China, strict regulatory approval processes make it difficult for manufacturers to bring products to market, limiting the availability of biomaterials. Concerns over disease transmission have also encouraged physicians to use autografts across BRIC countries, particularly as an alternative to allografts. However, the introduction of new products supported by clinical data through 2022 will offer the potential for rapid market growth as physicians increasingly recognize the benefits of these products and recommend them to patients. In addition to greater accessibility in physician practices, increasing economic prosperity will enable more patients to seek out traditionally expensive dental biomaterial procedures.
"Awareness of dental biomaterials has already risen substantially in Brazil," said DRG Analyst Kristina Vidug. "Manufacturers have invested significantly in improving overall awareness and confidence in biomaterials in Brazil through advertising and training programs for dentists. They have been particularly active in this regard because dental implants are widely accepted in Brazil due to the country's high aesthetic consciousness; this has led to a higher volume of procedures in which dental biomaterials can be incorporated. As a result, this market is highly penetrated and accounted for the largest proportion of dental biomaterials procedures performed in 2013. Although the Brazilian market will continue to generate the highest revenues through 2022, it will display the slowest growth due to the market's relative maturity."
The BRIC markets for dental biomaterials are largely dominated by international competitors with strong positions in other regions. For example, Geistlich's leading position is largely supported by its strong global reputation and its long history in the dental biomaterial market, which has helped fuel clinical confidence in the safety and efficacy of its products. Large multinational competitors also often offer multiple products in the dental field and will use their vast resources to conduct clinical trials for the use of multiple products in tandem, which encourages physicians to purchase multiple items from their product lines, further boosting revenues.
Decision Resources Group's BRIC Markets for Dental Biomaterials 2014 report includes unit, procedure, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for bone graft substitutes, dental membranes and tissue regeneration in Brazil, Russia, India and China.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
SOURCE Decision Resources Group